<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00571831</url>
  </required_header>
  <id_info>
    <org_study_id>Toshi-1</org_study_id>
    <secondary_id>showa-IRB-02503</secondary_id>
    <nct_id>NCT00571831</nct_id>
  </id_info>
  <brief_title>The Effect of a Blue Light Filtering IOL</brief_title>
  <official_title>The Effect of a Blue Light Filtering Intraocular Lens on Blood Retinal Barrier After Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Showa University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Showa University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect on blood retinal barrier disruption 3 and 12 months after implantation
      of either a blue light filtering intraocular lens(blue-filtering IOL) or an ultraviolet light
      filtering intraocular lens(UV-filtering IOL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The following parameters were measured for evaluation of blood retinal barrier disruption.

        -  the incidence of macular leakage by fluorescence angiography (FA)

        -  the mean fluorescein concentration in the vitreous by fluorophotometry (VFP)

        -  the thickness of the macula by optical coherence tomography (OCT)

      Results

        -  the incidence fo macular leakage decreased significantly from 24%(3 months) to 5% (12
           months) in the blue-filtering IOL group (P&lt;0.05), and was significantly lower compared
           with the UV-filtering IOL group at 12 months.

        -  the VFP significantly decreased in both group from 3 to 12 months.

        -  the OCT decreased from 175 (3 months) to 166 um (12 months) in the blue- filtering IOL
           group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To measure FA, VEP and OCT.</measure>
    <time_frame>At 3 and 12 months after IOL implantation</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>to Compare the Effect of Two Types of IOLs</condition>
  <condition>on the Incidence of Cystoid Macular Edema</condition>
  <condition>After Cataract Surgery</condition>
  <arm_group>
    <arm_group_label>letter</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>a blue-filtering IOL an UV-filtering IOL</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intraocular lens implantation</intervention_name>
    <description>Intraocular lens implantation</description>
    <arm_group_label>letter</arm_group_label>
    <other_name>a blue-filtering IOL (ENV-13, Menicon Co.Ltd, Japan)</other_name>
    <other_name>an UV-filtering IOL (ES-13, Menicon Co.Ltd, Japan)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cataract patients

          -  All eligible for intraocular lens implantation

        Exclusion Criteria:

          -  Patients had undergone an intraocular operation

          -  Patients had hypertensive retinopathy

          -  Patients had diabetic retinopathy

          -  Patients had ange-related macular degeneration

          -  no observable fundus

          -  The cataract operation was more than 30 minutes in duration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryohei Koide, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Ophthalmology, School of Medicine, Showa University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Showa University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2007</study_first_submitted>
  <study_first_submitted_qc>December 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2007</study_first_posted>
  <last_update_submitted>December 11, 2007</last_update_submitted>
  <last_update_submitted_qc>December 11, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2007</last_update_posted>
  <responsible_party>
    <name_title>Toshihiko Ueda/Associate Professor</name_title>
    <organization>Dept. of Ophthalmology, School of Medicine, Showa University</organization>
  </responsible_party>
  <keyword>macula edema</keyword>
  <keyword>intraocular lens</keyword>
  <keyword>prospective randomized parallel clinical design</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Capsule Opacification</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

